Scotia Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
Other funds holding PFE
VCM
VPM
Scotia Capital's PFE Position: Q1 2026 in Review
Scotia Capital reduced its Pfizer (PFE) stake by 3.8% in Q1 2026, selling an estimated $1.1M and leaving 1,058,826 shares worth $29.7M. The position accounts for 0.12% of the portfolio, ranked #104.
Scotia Capital first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $126M in Q4 2021. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Scotia Capital held 1,058,826 shares of Pfizer worth $29.7M as of Q1 2026.
- Scotia Capital sold 41,315 Pfizer shares in Q1 2026, an estimated $1.1M.
- Pfizer made up 0.12% of Scotia Capital's portfolio in Q1 2026, its #104 holding.
- Scotia Capital first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- Scotia Capital's Pfizer position peaked at $126M in Q4 2021.
- 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.